# Can You Advertise Simtriyo (Centanafadine)?

Reviewed November 3, 2026 · By Michael Borgia, MedScale Health

## Short answer

Yes, with approvals: DEA placed Simtriyo (centanafadine) in Schedule III effective October 30, 2026, and an ad that names it is a prescription drug ad, so Meta requires active LegitScript certification plus Meta's authorization and Microsoft requires preapproval. MedScale Health, a paid ads agency for US telehealth brands and clinics, runs ADHD campaigns on the evaluation and the clinician, and names Simtriyo only in ads those approvals cover. TikTok's drugs policy bars controlled drugs, so TikTok needs a written answer first.

## Can a telehealth brand advertise Simtriyo now?

A US telehealth brand can name Simtriyo (centanafadine) in ads now that DEA's rule placing it in Schedule III took effect on October 30, 2026, provided the brand holds each platform's prescription drug approval. MedScale Health, a paid ads agency for US telehealth brands and clinics, plans Simtriyo campaigns in that order: approvals first, then ads about [the ADHD evaluation and the clinician](https://medscale.health/answers/can-you-advertise-adhd-telehealth-on-meta-and-google), with the drug name only in ads an approval covers. This page is marketing guidance, not legal advice; check the sources at the end before acting on a rule.

- FDA approved Simtriyo on July 24, 2026 for ADHD in adults and in children 6 and older who weigh at least 20 kg.
- DEA's interim final rule placed centanafadine in Schedule III, effective October 30, 2026, with comments open until November 30, 2026.
- Meta needs active LegitScript certification and Meta's authorization before an ad promotes Simtriyo, with adults only and a prescription disclaimer.
- Microsoft needs telemedicine providers that sell prescription drugs to be preapproved.
- TikTok's drugs policy bars controlled drugs, so get TikTok's answer in writing before planning Simtriyo ads there.

## What changed for Simtriyo on October 30, 2026?

DEA published its centanafadine rule in the Federal Register on October 30, 2026 as document 2026-22208, and the rule states, "This rule is effective October 30, 2026." DEA says it "is hereby issuing an interim final rule placing centanafadine" in Schedule III of the Controlled Substances Act, and comments can be submitted until November 30, 2026. The rule explains that this fast scheduling path exists so that newly approved drugs with abuse potential "may be marketed without undue delay following FDA approval."

FDA lists Simtriyo among its 2026 novel drug approvals with a July 24, 2026 date. The prescribing label calls it a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant for ADHD in adults and pediatric patients 6 and older weighing at least 20 kg. Under the DEA rule, every prescription must comply with 21 U.S.C. 829 and be issued under 21 CFR parts 1306 and 1311, subpart C. MedScale Health treats Simtriyo as a Schedule III prescription drug in every ad plan from October 30, 2026.

## Does a Meta ad that names Simtriyo need LegitScript and Meta's authorization?

A Meta ad that names Simtriyo is a prescription drug ad, so it needs both. Meta's Drugs and Pharmaceuticals policy says "Meta requires online pharmacies and telehealth providers to be actively certified with LegitScript," and once certified they must [request authorization from Meta](https://medscale.health/answers/meta-prescription-drug-authorization-steps). Approved ads must include a disclaimer to consult a licensed health professional or obtain a valid prescription, and can target only people 18 or older in countries where the advertiser is certified. Ads that promote telehealth services generally need no written authorization, so an ADHD evaluation ad that leaves the drug out can run while the approvals are pending.

Two more Meta standards apply to every ADHD ad. [The personal attributes policy](https://medscale.health/answers/mental-health-ad-copy-examples) bars ads that assert or imply a person's physical or mental health, and Meta's own failing example is "Depression getting you down? Get help now." The drugs policy bars ads that encourage the consumption of potentially unsafe drugs. MedScale writes Simtriyo ads to name the evaluation, the clinician and the treatment, never the viewer's symptoms.

## Can Microsoft or TikTok ads promote Simtriyo?

[Microsoft Advertising can, after preapproval](https://medscale.health/answers/microsoft-ads-for-telehealth). Its healthcare policy, last updated October 5, 2026, says "Online pharmacies, telemedicine providers that sell prescription drugs, and prescription drug manufacturers must be preapproved in order to serve ads on the Microsoft Advertising network." Ads that promote prescription drugs must not target users based on sensitive health information, must advise consumers to follow label directions, and must warn that the recommended dose should not be exceeded.

TikTok is the open question. Its drugs policy says, "We do not allow ad content and landing pages to display, promote, sell, solicit, or provide access to illegal drugs, controlled drugs, prescription drug abuse, recreational drugs, drug paraphernalia, accessories, supplies, or their use." The same section allows prescription drugs in the United States and Canada when a regulator has approved them, the claims are accurate and viewers are 18 or older, but it does not say whether that exception covers controlled drugs. Simtriyo is now a controlled drug, so MedScale plans Simtriyo ads without TikTok unless TikTok confirms the plan in writing.

## How does the DEA's December 31, 2026 telemedicine date affect Simtriyo ads?

Telehealth prescribing of Simtriyo currently rests on [temporary DEA flexibilities](https://medscale.health/answers/dea-telemedicine-rule-2026-advertising). HHS's telehealth site says DEA and HHS extended the full set of telemedicine flexibilities for prescribing controlled medications "through December 31, 2026," and that "A DEA-registered practitioner can prescribe a schedule II-V controlled substance to a patient using telemedicine without having conducted an in-person medical evaluation if required conditions are met." Schedule III falls inside that range.

The permanent rule is still pending. The White House regulatory review list shows DEA's final rule on special registrations for telemedicine, RIN 1117-AB40, received on August 25, 2026 and still under review on November 3, 2026. An ad or landing page that promises ADHD medication with no in-person visit, ever, could be overtaken by that rule. MedScale writes Simtriyo copy around the evaluation and a licensed clinician's decision, so the ads still read true if the rules change after December 31, 2026.

## What does Simtriyo's boxed warning mean for ad copy?

Simtriyo's label carries a boxed warning for suicidal ideation and behaviors in pediatric patients aged 6 and older, and for abuse, misuse and addiction. The label says Simtriyo "has a potential for abuse and misuse" and tells prescribers to assess each patient's risk for abuse, misuse and addiction before prescribing. Ad copy that makes a prescription sound quick, certain or easy sits badly next to that warning. MedScale keeps speed-to-prescription promises out of Simtriyo ads, says a licensed clinician decides whether medication is appropriate, and aims every Simtriyo ad at adults.

## How does MedScale run ADHD ads that include Simtriyo?

MedScale runs Simtriyo inside a [wider ADHD evaluation and care program](https://medscale.health/telehealth/mental-health). The first campaigns promote the evaluation and the clinicians, which Meta allows without authorization. Simtriyo ads go into their own ad sets once LegitScript certification and Meta's authorization are in place, and Microsoft campaigns follow preapproval. Every ad and landing page is checked against the named platform rule before it spends, and the campaign goal is a booked evaluation. A new ADHD telehealth brand can start with [MedScale's launch plan](https://medscale.health/build), and a brand with live campaigns can [book the free growth audit](https://medscale.health/audit).

## Next step

**Check your ad before Meta does.** Paste your ad copy into the free pre-check. It flags the lines a reviewer reads as personal attributes, outcome promises or drug claims.

- [Run the free pre-check](https://medscale.health/pre-check)
- [Already restricted? Start a rescue](https://medscale.health/rescue)
- [Telehealth marketing agency](https://medscale.health/telehealth)
- [Get a free Growth Audit](https://medscale.health/audit): a written read of your ads, pages and eligibility, with a plan

## FAQ

**Is Simtriyo a controlled substance?**

Yes. DEA placed centanafadine, sold as Simtriyo, in Schedule III of the Controlled Substances Act through an interim final rule effective October 30, 2026, Federal Register document 2026-22208. Every prescription must comply with 21 U.S.C. 829.

**Is Simtriyo a stimulant?**

Yes. Simtriyo's FDA label describes it as a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant for ADHD, and its boxed warning covers abuse, misuse and addiction as well as suicidal ideation and behaviors in pediatric patients.

**Can an ADHD telehealth company run Facebook ads for Simtriyo?**

Yes, once it is actively certified with LegitScript and authorized by Meta. The ads must target people 18 or older, include a disclaimer to consult a licensed health professional or obtain a valid prescription, and avoid implying the viewer has ADHD.

**Can a telehealth provider prescribe Simtriyo without an in-person visit?**

Through December 31, 2026, yes, if the required conditions are met: HHS says a DEA-registered practitioner can prescribe a Schedule II to V controlled substance by telemedicine without an in-person evaluation. DEA's permanent telemedicine rule is still under White House review.

**Does Simtriyo's Schedule III status change TikTok ads?**

It makes them harder to plan. TikTok's drugs policy bars ads and landing pages that promote controlled drugs, and its US exception for approved prescription drugs does not say it covers them, so MedScale keeps Simtriyo off TikTok unless TikTok confirms the plan in writing.

## Sources

- [Federal Register 2026-22208: Schedules of Controlled Substances: Placement of Centanafadine in Schedule III (DEA interim final rule, effective Oct 30, 2026)](https://www.federalregister.gov/documents/2026/10/30/2026-22208/schedules-of-controlled-substances-placement-of-centanafadine-in-schedule-iii) (checked November 3, 2026)
- [FDA: Novel Drug Approvals for 2026 (Simtriyo, 7/24/2026)](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026) (checked November 3, 2026)
- [FDA: Simtriyo (centanafadine) extended-release capsules, prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218145s000lbl.pdf) (checked November 3, 2026)
- [Meta Advertising Standards: Drugs and Pharmaceuticals (prescription drugs)](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/) (checked November 3, 2026)
- [Meta Advertising Standards: Privacy Violations and Personal Attributes](https://transparency.meta.com/policies/ad-standards/objectionable-content/privacy-violations-personal-attributes/) (checked November 3, 2026)
- [Microsoft Advertising policy: Healthcare and Pharmaceutical (last updated Oct 5, 2026)](https://help.ads.microsoft.com/#apex/ads/en/60379/-1) (checked November 3, 2026)
- [TikTok Ads policy: Dangerous Products or Services (Drugs section)](https://ads.tiktok.com/resources/help/article/tiktok-ads-policy-dangerous-products-or-services) (checked November 3, 2026)
- [TikTok Ads policy: Healthcare and Pharmaceuticals (United States section)](https://ads.tiktok.com/resources/help/article/tiktok-ads-policy-healthcare-pharmaceuticals) (checked November 3, 2026)
- [Telehealth.HHS.gov: Prescribing controlled substances via telehealth (flexibilities through Dec 31, 2026)](https://telehealth.hhs.gov/providers/telehealth-policy/prescribing-controlled-substances-via-telehealth) (checked November 3, 2026)
- [OIRA: Executive Order 12866 rules under review (DEA RIN 1117-AB40, special registrations for telemedicine, received Aug 25, 2026)](https://www.reginfo.gov/public/do/XMLViewFileAction?f=EO_RULES_UNDER_REVIEW.xml) (checked November 3, 2026)

## Related

- [Can You Advertise ADHD Telehealth on Meta and Google?](https://medscale.health/answers/can-you-advertise-adhd-telehealth-on-meta-and-google)
- [What Does the DEA Telemedicine Rule Mean for Telehealth Ads in 2026?](https://medscale.health/answers/dea-telemedicine-rule-2026-advertising)
- [How Do You Get Meta's Authorization to Advertise Prescription Drugs?](https://medscale.health/answers/meta-prescription-drug-authorization-steps)
- [Can Telehealth Brands Advertise on Microsoft Ads (Bing)?](https://medscale.health/answers/microsoft-ads-for-telehealth)

Canonical page: https://medscale.health/answers/can-you-advertise-simtriyo-centanafadine